Open AccessJournal Article
Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).
M C Béné,Gian Luigi Castoldi,Walter Knapp,Wolf-Dieter Ludwig,Estella Matutes,A. Orfao,van't Veer Mb +6 more
Reads0
Chats0
TLDR
The main aims of EGIL are to establish guidelines for the characterization of acute leukemias based on marker expression and provide a uniform basis for the diagnosis of the various types of these hemopoietic malignancies which should be helpful for future multinational clinical and laboratory investigations.Abstract:
Criteria for the immunological classification of acute leukemias are proposed by a recently established European group designated EGIL. The main aims of EGIL are to establish guidelines for the characterization of acute leukemias based on marker expression and provide a uniform basis for the diagnosis of the various types of these hemopoietic malignancies which should be helpful for future multinational clinical and laboratory investigations. Within the two major types (B and T cell lineage) of acute lymphoblastic leukemia (ALL), several groups are delineated according to the degree of cell differentiation. Within the acute myeloid leukemias (AML), only three subtypes as defined by the FAB classification: M0-AML, M6-AML and M7-AML, can be unequivocally defined by immunological markers; prospective studies are undertaken to see whether characteristic immunological profiles are associated with particular AML subtypes defined by specific cytogenetic abnormalities. Criteria for the definition of biphenotypic acute leukemia (BAL) are devised and a scoring system is outlined aimed to distinguish BAL from those acute leukemias with expression of a marker from another lineage. In addition, an uncommon subset of acute leukemias with no evidence of lymphoid or myeloid differentiation is recognized and the useful panel of markers to investigate and establish the cell nature of the acute leukemias is outlined. EGIL will focus in the future on testing the reproducibility of the proposed guidelines, particularly those for BAL, assessing their clinical value within a framework of multicentric trials and setting up uniform methodological criteria.read more
Citations
More filters
Journal ArticleDOI
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Hartmut Döhner,Elihu H. Estey,Sergio Amadori,Frederick R. Appelbaum,Thomas Büchner,Alan Kenneth Burnett,Hervé Dombret,Pierre Fenaux,David Grimwade,Richard A. Larson,Francesco Lo-Coco,Tomoki Naoe,Dietger Niederwieser,Gert J. Ossenkoppele,Miguel A. Sanz,Jorge Sierra,Martin S. Tallman,Bob Löwenberg,Clara D. Bloomfield +18 more
TL;DR: An international expert panel is provided to provide updated evidence- and expert opinion-based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials.
Journal ArticleDOI
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia
Adolfo A. Ferrando,Donna Neuberg,Jane Staunton,Mignon L. Loh,Christine Huard,Susana C. Raimondi,Fred G. Behm,Ching-Hon Pui,James R. Downing,D. Gary Gilliland,Eric S. Lander,Todd R. Golub,A. Thomas Look +12 more
TL;DR: It is shown that five different T cell oncogenes are often aberrantly expressed in the absence of chromosomal abnormalities, and HOX11L2 activation is identified as a novel event in T cell leukemogenesis.
Journal ArticleDOI
Acute myeloid leukaemia.
Asim Khwaja,Magnus Björkholm,Rosemary E. Gale,Ross L. Levine,Craig T. Jordan,Gerhard Ehninger,Clara D. Bloomfield,Eli Estey,Alan Kenneth Burnett,Jan J. Cornelissen,David A. Scheinberg,Didier Bouscary,David C. Linch +12 more
TL;DR: A plethora of new agents — including those targeted at specific biochemical pathways and immunotherapeutic approaches — are now in trial based on improved understanding of disease pathophysiology, providing good grounds for optimism, although mortality remains high especially in older patients.
Journal ArticleDOI
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.
J. J. M. Van Dongen,Ludovic Lhermitte,S Böttcher,Julia Almeida,V H J van der Velden,Juan Flores-Montero,Andy C. Rawstron,Vahid Asnafi,Quentin Lecrevisse,Paulo Sérgio Lucio,Ester Mejstrikova,Tomasz Szczepański,Tomas Kalina,R de Tute,Monika Brüggemann,Lukasz Sedek,M Cullen,Anthonie Willem Langerak,Alexandre de Mendonça,Elizabeth Macintyre,Marta Martin-Ayuso,Ondrej Hrusak,M B Vidriales,Alberto Orfao +23 more
TL;DR: The EuroFlow studies resulted in validated and flexible 8-color antibody panels for multidimensional identification and characterization of normal and aberrant cells, optimally suited for immunophenotypic screening and classification of hematological malignancies.
Journal ArticleDOI
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study
Valentino Conter,Claus R. Bartram,Maria Grazia Valsecchi,André Schrauder,Renate Panzer-Grümayer,Anja Möricke,Maurizio Aricò,Martin Zimmermann,Georg Mann,Giulio Rossi,Martin Stanulla,Franco Locatelli,Giuseppe Basso,Felix Niggli,Elena Barisone,Guenter Henze,Wolf-Dieter Ludwig,Oskar A. Haas,Giovanni Cazzaniga,Rolf Koehler,Daniela Silvestri,Jutta Bradtke,Rosanna Parasole,Rita Beier,Jacques J.M. van Dongen,Andrea Biondi,Martin Schrappe +26 more
TL;DR: Standardized quantitative assessment of minimal residual disease based on immunoglobulin and T-cell receptor gene rearrangements as polymerase chain reaction targets (PCR-MRD) at 2 time points (TPs) is introduced, to stratify patients in a large prospective study.
Related Papers (5)
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Andrew P. Weng,Andrew P. Weng,Adolfo A. Ferrando,Adolfo A. Ferrando,Woojoong Lee,Woojoong Lee,John P. Morris,John P. Morris,Lewis B. Silverman,Lewis B. Silverman,Cheryll Sanchez-Irizarry,Cheryll Sanchez-Irizarry,Stephen C. Blacklow,Stephen C. Blacklow,A. Thomas Look,A. Thomas Look,Jon C. Aster,Jon C. Aster +17 more